Corporate Sustainability and Social Impact Report

The report describes Jazz Pharmaceuticals' 2025 CSSI progress, including FDA approval and launch of Modeyso, the first treatment for recurrent H3 K27M-mutant diffuse midline glioma, and expanded patient engagement. It sets an absolute Scope 1 and 2 GHG reduction target of 35% by 2030 from a 2025 baseline and reports renewable electricity across all internal manufacturing sites and one corporate office. It also highlights the first company-wide Wellbeing Week and 84% employee survey participation, while KPMG provided limited assurance over Scope 1 and Scope 2 emissions.